佐剂正在复兴
2026年八月27日 For many years, adjuvants were viewed by many in the agricultural world as optional, especially if users were concerned about spray drift issues in crop fields. However, in 2024 for the U.S. market, this changed.
That was the year that U.S. Environmental Protection Agency (EPA) began introducing new regulations for crop protection product applications tied to the Endangered Species Act (ESA). As Terry Kippley, President and CEO at the 农业技术生产者和分销商委员会 (CPDA), explains, this represented a game-changer for the adjuvants category.
“Before 2025, drift reduction and soil retention adjuvants showed up as tiny blips on a farm’s radar screen,” says Kippley. “Now, they are valuable tools to help the industry meet the ESA requirements.”
Increasing Demand
According to EPA, the goal of the ESA is “to develop a broad approach to address spray drift and runoff transport from treated fields to minimize exposure” for wildlife and plants. Since these new requirements began appearing, adjuvant companies have noted a definite uptick in product demand.
“(ESA has) quietly became the strongest regulatory driver in adjuvant innovation and use,” says Landon Bunderson, Chief Science Officer at 纳米产量. “When label changes reflect lower use rates and decreased frequency, the industry must do more with less. What that ultimately means for the grower is, ‘I better make sure that I’m hitting my target with the most potency possible.’”
Biological Efficacy
Another development for adjuvants is that U.S. growers have increasingly turned to biologicals in their crop fields, with a need for compatible adjuvants. These products, added to the application mix, can help with efficacy and handling.
“We see the adjuvants market for biologicals as early stage but growing quickly,” says Ganesh Sanganwar, Ph.D., Business Development Manager at 西恩斯科. “What is clear is that biological adoption is increasing and expanding beyond high value crops, creating a stronger need for adjuvant technologies that make biological products easier to handle and more consistent in the field. We believe adjuvants will grow with biologicals but also contribute greatly to their larger adoption by enabling them to bridge the performance gap with traditional inputs.”
The numbers seem to back up Sanganwar’s assertion. According to the data, the U.S. biologicals market was estimated to be worth approximately $5 billion in 2025, with a projected compound annual growth rate of between 8% and 13% through 2030. Market watchers credit the rise in regenerative agriculture, carbon programs, and precision agriculture for much of this projected growth, not to mention the increasing popularity of organic farming.
“The status of the adjuvant market for biologicals is one of opportunity, for both in-can formulation development and tank mix adjuvants, in which shelf life, handling, and performance can be addressed,” says Gregory Lindner, Research Director at Croda Inc. “The adjuvant market specifically for biologicals as a sole treatment is currently small but growing and likely to parallel the growth of the biopesticide market for ‘organic-certified’ production environments.”
在 AgriBusiness Global 上阅读更多类似文章 2026年佐剂深度解析.
立即获取时事通讯！
